» Articles » PMID: 38444892

Therapeutic Inertia

Overview
Journal Aust Prescr
Date 2024 Mar 6
PMID 38444892
Authors
Affiliations
Soon will be listed here.
Abstract

Therapeutic inertia, sometimes referred to as clinical inertia, has been defined as failure to initiate or intensify therapy when therapeutic goals are not reached. Lack of initiation or intensification of treatment according to clinical guidelines has been linked to suboptimal control of a range of chronic conditions. Clinician factors contributing to therapeutic inertia include knowledge gaps; discomfort with uncertainty about the diagnosis, therapeutic target, or evidence; concerns about the safety of treatment intensification; and time constraints. Patient characteristics that may be associated with therapeutic inertia include male sex, older age, lower life expectancy, multiple comorbidities and clinical parameters that are close to target. There may be reasons other than therapeutic inertia that explain apparent undertreatment. Apparent inertia in prescribing may be accompanied by appropriate actions, such as provision of lifestyle advice or interventions to promote adherence to existing medication. Some patients choose not to intensify treatment. Interventions to reduce therapeutic inertia include access to evidence-based treatment guidelines and point-of-care tools, preferably integrated with clinical record systems; clinician education including educational visits; reminders; clinical audits with feedback and reflection on practice; shared decision-making; prompting by patients; and ambulatory or home monitoring (e.g. ambulatory blood pressure monitoring).

Citing Articles

Improving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases: A Call-to-Action from the Middle East.

Almahmeed W, Alabadla Z, Al Awadi F, Alrohmaihi D, AlShamiri M, Elbadawi H Adv Ther. 2025; 42(3):1340-1359.

PMID: 39841371 PMC: 11868338. DOI: 10.1007/s12325-024-03103-5.


Statin-Associated Muscle Symptoms: Identification and Recommendations for Management.

Maki K, Kirkpatrick C, Cheeley M, Jacobson T Curr Atheroscler Rep. 2024; 27(1):5.

PMID: 39556289 DOI: 10.1007/s11883-024-01246-y.

References
1.
Bruckert E, Parhofer K, Gonzalez-Juanatey J, Nordestgaard B, Arca M, Giovas P . Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review. Adv Ther. 2020; 37(5):1724-1736. PMC: 7467492. DOI: 10.1007/s12325-020-01285-2. View

2.
Kario K, Harada N, Okura A . Digital Therapeutics in Hypertension: Evidence and Perspectives. Hypertension. 2022; 79(10):2148-2158. PMC: 9444254. DOI: 10.1161/HYPERTENSIONAHA.122.19414. View

3.
Rea F, Corrao G, Merlino L, Mancia G . Initial Antihypertensive Treatment Strategies and Therapeutic Inertia. Hypertension. 2018; 72(4):846-853. DOI: 10.1161/HYPERTENSIONAHA.118.11308. View

4.
Milman T, Joundi R, Alotaibi N, Saposnik G . Clinical inertia in the pharmacological management of hypertension: A systematic review and meta-analysis. Medicine (Baltimore). 2018; 97(25):e11121. PMC: 6025046. DOI: 10.1097/MD.0000000000011121. View

5.
Yan X, Mudiganti S, Husby H, Hudnut A, Gbotoe M, Jones J . Medication non-adherence and therapeutic inertia independently contribute to poor disease control for cardiometabolic diseases. Sci Rep. 2022; 12(1):18936. PMC: 9640683. DOI: 10.1038/s41598-022-21916-8. View